Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24\hspace0.167emmg/dayстатья

Статья опубликована в журнале из списка Web of Science и/или Scopus